LUX-Breast 3 Clinical Trial Infographic

01.12.2011

• Female patients aged 18 years or older
• Patients with HER2+ breast cancer with a documented central nervous system (CNS) recurrence/progression (by imaging) during or after a HER2 (ErbB2) inhibitor (trastuzumab or lapatinib) based therapy
• At least one measurable and progressive lesion in the brain
• Previous treatment with HER2 inhibitors to be discontinued at least 14 days prior to first study treatment administration
• Prior chemotherapy must have been discontinued at least 14 days for trastuzumab and 7 days for lapatinib and hormonal therapy at least 7 days prior to first study treatment
• Patients must have recovered to baseline condition or to Common Terminology Criteria for Adverse Events (CTCAE)
• Prior surgery, whole brain radiotherapy or stereotactic radiosurgery allowed, provided that there is unequivocal evidence of one or more new and/or progressive brain metastases after completion of whole brain radiotherapy or stereotactic radiosurgery